Industry Briefs: February 11, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: February 11, 2013
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company News

Almac has undergone a successful inspection of its new US Commercial Packaging operations located in Audubon, Pennsylvania, by FDA. The inspection took place on Jan. 9–10, 2013 from which the regulatory body concluded that aforementioned site is fully compliant with GMPs, with no 483 issued. Read More

AMRI has signed an exclusive license agreement with Chai Therapeutics, an affiliate of Bessor Pharma, for the development of ALB 109564(a), AMRI’s tubulin inhibitor compound in late Phase I testing for treating cancer. The agreement follows the exercise of an option to license the intellectual property, which was granted in March 2012 by AMRI to Bessor Pharma, a translational drug development company. Read More

FDA has approved Celgene’s Pomalyst (pomalidomide) therapy new molecular entity for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Read More

Gilead Sciences completed its acquisition of YM BioSciences on Feb. 8, 2013. Read More

MeadWestvaco, a provider of packaging and packaging services, has expanded its pharmaceutical manufacturing Centre of Excellence, based in Hemer, Germany. The Centre is the core for MWV’s global pharmaceutical-dispensing systems manufacturing network. The $7.5-million project includes expanding cleanroom molding and assembly capacity, and the introduction of a logistics system to control the flow of finished goods and components. Read More

Pergamum and Cadila Pharmaceuticals have formed a collaboration to develop a treatment of infections with a targeting mechanism distinguished from classical antibiotics. The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide that has been developed by Pergamum. The development will be conducted at the facilities of Cadila Pharmaceuticals in Ahmedabad, India. Cadila will be responsible for all costs related to the development of the product up to Phase II and global rights will be shared between the companies. Read More

Perrigo Company has completed the acquisition of Leeds, United Kingdom-based Rosemont Pharmaceuticals for approximately £180 million ($283 million) in cash. Read More

Pharmaceutical Product Development (PPD) has expanded its central laboratory testing services in infectious diseases. PPD has expanded its testing capabilities at its Brussels and Singapore laboratories, offering additional microbiology, peripheral blood mononuclear cell and molecular pathology services. Read More

Tranzyme’s board of directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction to maximize value to its stockholders. Read More

UPS has expansded its global healthcare distribution network in five markets in North America. Expanding locations include facilities in Burlington, Ontario; Louisville, Kentucky; Mira Loma, California; Atlanta, Georgia; and Reno, Nevada. The new expansions add nearly 800,000-ft2 to UPS’s global network of 37 dedicated healthcare facilities, which now total nearly 6 million ft2 of distribution space. Read More

People News

BASi has named Jacqueline Lemke president and CEO. Read More

Mylan has appointed Melina Higgins and Rajiv Malik to its board of directors. Read More

Teva Pharmaceuticals has appointed Arie Belldegrun to its board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here